121 related articles for article (PubMed ID: 11722418)
1. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back.
Nakamura R; Bahceci E; Read EJ; Leitman SF; Carter CS; Childs R; Dunbar CE; Gress R; Altemus R; Young NS; Barrett AJ
Br J Haematol; 2001 Oct; 115(1):95-104. PubMed ID: 11722418
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
3. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
[TBL] [Abstract][Full Text] [Related]
5. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
[TBL] [Abstract][Full Text] [Related]
7. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
[TBL] [Abstract][Full Text] [Related]
8. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies.
Bahçeci E; Read EJ; Leitman S; Childs R; Dunbar C; Young NS; Barrett AJ
Br J Haematol; 2000 Feb; 108(2):408-14. PubMed ID: 10691874
[TBL] [Abstract][Full Text] [Related]
9. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
11. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back.
Bornhäuser M; Platzbecker U; Theuser C; Hölig K; Ehninger G
Br J Haematol; 2002 Sep; 118(4):1095-103. PubMed ID: 12199791
[TBL] [Abstract][Full Text] [Related]
12. Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias.
Bunin N; Aplenc R; Grupp S; Pierson G; Monos D
Bone Marrow Transplant; 2006 Jan; 37(2):143-9. PubMed ID: 16284615
[TBL] [Abstract][Full Text] [Related]
13. Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back.
Rodríguez-Luaces M; Ferrá C; Martín-Henao G; Berlanga JJ; Grañena A; Gallardo D
Eur J Haematol; 2004 Sep; 73(3):162-8. PubMed ID: 15287912
[TBL] [Abstract][Full Text] [Related]
14. T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients.
Geyer MB; Ricci AM; Jacobson JS; Majzner R; Duffy D; Van de Ven C; Ayello J; Bhatia M; Garvin JH; George D; Satwani P; Harrison L; Morris E; Semidei-Pomales M; Schwartz J; Alobeid B; Baxter-Lowe LA; Cairo MS
Br J Haematol; 2012 Apr; 157(2):205-19. PubMed ID: 22313507
[TBL] [Abstract][Full Text] [Related]
15. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
[TBL] [Abstract][Full Text] [Related]
16. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Czerw T; Labopin M; Schmid C; Cornelissen JJ; Chevallier P; Blaise D; Kuball J; Vigouroux S; Garban F; Lioure B; Fegueux N; Clement L; Sandstedt A; Maertens J; Guillerm G; Bordessoule D; Mohty M; Nagler A
Oncotarget; 2016 May; 7(19):27255-66. PubMed ID: 27036034
[TBL] [Abstract][Full Text] [Related]
17. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
Rizzieri DA; Dev P; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Chao NJ
Bone Marrow Transplant; 2009 Feb; 43(4):327-33. PubMed ID: 18850014
[TBL] [Abstract][Full Text] [Related]
18. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings.
Urbano-Ispizua A; Rozman C; Pimentel P; Solano C; de la Rubia J; Brunet S; Pérez-Oteiza J; Ferrá C; Zuazu J; Caballero D; Carvalhais A; Díez JL; Espigado I; Martínez C; Campilho F; Sanz MA; Sierra J; García-Conde J; Montserrat E;
Blood; 2001 Jan; 97(2):383-7. PubMed ID: 11154212
[TBL] [Abstract][Full Text] [Related]
19. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
20. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation].
Zhou Z; Wang M; He Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
